scholarly journals Merkel cell carcinoma of the Auricle: A treacherous skin tumor

2012 ◽  
Vol 8 (3) ◽  
pp. 460 ◽  
Author(s):  
Arvind Krishnamurthy ◽  
Urmila Majhi
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Skin Tumor ◽  
Merkel Cell

Differentiating Merkel cell carcinoma of lymph nodes without a detectable primary skin tumor from other metastatic neuroendocrine carcinomas: The ELECTHIP criteria

2018 ◽  
Vol 78 (5) ◽  
pp. 964-972.e3 ◽  
Author(s):  
Thibault Kervarrec ◽  
Julia Zaragoza ◽  
Pauline Gaboriaud ◽  
Amélie Le Gouge ◽  
Agnès Beby-Defaux ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Skin Tumor ◽  
Merkel Cell ◽  
Neuroendocrine Carcinomas

scholarly journals Brain metastasis of Merkel cell carcinoma – A rare case report

2019 ◽  
Vol 10 ◽  
pp. 172
Author(s):  
Ricardo Lourenço Caramanti ◽  
Feres Eduardo Chaddad Neto ◽  
Lucas Crociati Meguins ◽  
Carlos Eduardo Rocha ◽  
Dionei Freitas de Moraes ◽  
...  
Keyword(s):  
Brain Metastasis ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Adjuvant Treatment ◽  
Treatment Options ◽  
Skin Tumor ◽  
Merkel Cell ◽  
Left Frontal Lobe ◽  
Perilesional Edema ◽  
Rare Case Report

Background: Merkel cell carcinoma (MCC) is a rare neuroendocrine skin tumor. In our knowledge, only 30 cases of brain metastasis were reported in literature. The authors report a case of 57-year-old male with elevated intracranial pressure signs, which a frontal mass with pathological diagnosis of MCC. Case Description: A 57-year-old male was admitted with a 3-month history of progressive headache, associated with nausea and dizziness. The magnetic resonance imaging showed a left frontal lobe, parasagittal, and nodular lesion with perilesional edema. The patient underwent complete surgical resection with success. The adjuvant treatment was radiotherapy and chemotherapy. Conclusion: In our knowledge, there is a little number of cases of MCC reported in literature. Surgical management is considered in cases with intracranial hypertension or focal signs. The adjuvant treatment options are immunotherapy and radiotherapy.

scholarly journals COST-EFFECTIVENESS ANALYSIS OF AVELUMAB TREATMENT FOR PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA

2020 ◽  
Vol 66 (2) ◽  
pp. 109-119
Author(s):  
Nikolay Avksentev ◽  
Lev Demidov ◽  
Maksim Frolov ◽  
Aleksandr Makarov
Keyword(s):  
Cost Effectiveness ◽  
Incremental Cost ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Skin Tumor ◽  
Line Treatment ◽  
Second Line ◽  
Merkel Cell ◽  
Life Years

Merkel cell carcinoma (MCC) is a rare primary malignant skin tumor with epithelial and neuroendocrine differentiation. According to the Russian clinical recommendations, MCC accounts for around 650 new cases per year in Russia. Avelumab is a human IgG1 monoclonal antibody that targets cancer cells through the inhibition of the immune checkpoint protein PD-L1 and can be used as a 2nd line treatment of metastatic MCC (mMCC). The aim of the study is to conduct a clinical and economic evaluation of avelumab as a second-line treatment in patients with mMCC from the perspective of Russian health care. Methods. Standard chemotherapy regimens were considered as a comparator for avelumab. We proposed a mathematical model of MCC progression and calculated direct medical costs during 6 years of treatment. Incremental cost-effectiveness ratios for avelumab (vs chemotherapy) were compared with the corresponding ratios for another PD-1 inhibitor included in Vital and Essential Drug List (VEDL). Results. Life-years gained (LYG) for avelumab were 2.21 years, compared to 0.39 LYG for chemotherapy. The average costs of using avelumab were 9 156 731 RUB per patient, compared to 60 743 RUB when using chemotherapy. Incremental cost-effectiveness ratio (ICER) for avelumab (vs chemotherapy) was 5 012 867.70 RUB per one LYG, which was 54.8% lower than ICER for pembrolizumab (vs docetaxel) as a second-line treatment in patients with non-small cell lung cancer. ICER for avelumab vs chemotherapy was 11,940,043.38 RUB per one progression-free LYG, which was 40.9% lower than ICER for pembrolizumab (vs chemotherapy) as a treatment in patients with ipilimumab-refractory advanced melanoma.

scholarly journals Concurrent Chronic Lymphocytic Leukemia and Merkel Cell Carcinoma in Primary Skin Tumor and Metastatic Lymph Node

2014 ◽  
Vol 30 (S1) ◽  
pp. 422-424 ◽  
Author(s):  
Lazar Popovic ◽  
Darjana Jovanovic ◽  
Dragana Petrovic ◽  
Zoran Nikin ◽  
Gorana Matovina-Brko ◽  
...  
Keyword(s):  
Lymph Node ◽  
Chronic Lymphocytic Leukemia ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Metastatic Lymph Node ◽  
Lymphocytic Leukemia ◽  
Skin Tumor ◽  
Merkel Cell ◽  
Metastatic Lymph

scholarly journals Merkel cell carcinoma-A rare primary neuroendocrine skin tumor: Case report and discussion

2014 ◽  
Vol 10 (2) ◽  
pp. 437 ◽  
Author(s):  
Nidhi Gupta ◽  
ShivpreetSingh Samra ◽  
Vinod Nimbran ◽  
RakeshKumar Gupta ◽  
AshwinAnand Kallianpur ◽  
...  
Keyword(s):  
Case Report ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Skin Tumor ◽  
Merkel Cell

scholarly journals Intron 4–5 hTERT DNA Hypermethylation in Merkel Cell Carcinoma: Frequency, Association with Other Clinico-pathological Features and Prognostic Relevance

2021 ◽  
Author(s):  
Costantino Ricci ◽  
Luca Morandi ◽  
Francesca Ambrosi ◽  
Alberto Righi ◽  
Dino Gibertoni ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Skin Tumor ◽  
Epigenetic Mechanism ◽  
Merkel Cell ◽  
Pathological Features ◽  
Intron 4 ◽  
Overall Mortality

AbstractMerkel cell carcinoma (MCC) is an aggressive skin tumor with neuroendocrine differentiation, mainly affecting elderly population or immunocompromised individuals. As methylation of the human telomerase reverse transcriptase (mhTERT) has been shown to be a prognostic factor in different tumors, we investigated its role in MCC, in particular in intron 4–5 where rs10069690 has been mapped and recognized as a cancer susceptibility locus. DNA methylation analysis of hTERT gene was assessed retrospectively in a cohort of 69 MCC patients from the University of Bologna, University of Turin and University of Insubria. Overall mortality was evaluated with Kaplan-Meier curves and multivariable Royston-Parmar models. High levels of mhTERT (mhTERThigh) (HR = 2.500, p = 0.015) and p63 (HR = 2.659, p = 0.016) were the only two clinico-pathological features significantly associated with a higher overall mortality at the multivariate analysis. We did not find different levels of mhTERT between MCPyV (+) and (−) cases (21 vs 14, p = 0.554); furthermore, mhTERThigh was strongly associated with older age (80.5 vs 72 years, p = 0.026), no angioinvasion (40.7% vs 71.0%, p = 0.015), lower Ki67 (50 vs 70%, p = 0.005), and PD-L1 expressions in both tumor (0 vs 3%, p = 0.021) and immune cells (0 vs 10%, p = 0.002). mhTERT is a frequently involved epigenetic mechanism and a relevant prognostic factor in MCC. In addition, it belongs to the shared oncogenic pathways of MCC (MCPyV and UV-radiations) and it could be crucial, together with other epigenetic and genetic mechanisms as gene amplification, in determining the final levels of hTERT mRNA and telomerase activity in these patients.

scholarly journals CYTOLOGICAL DIAGNOSTICS OF MERKEL CELL CARCINOMA (PRIMARY NEURO-ENDOCRINE SKIN CANCER) IN THE MATERIAL OF A SUPERFICIAL SHAVE BIOPSY

2021 ◽  
pp. 54-58
Author(s):  
V. N. Vysotskaya ◽  
Y. V. Karpova ◽  
E. S. Sukhovskaya ◽  
A. V. Babushkin ◽  
Ni. V. Boriskin
Keyword(s):  
Skin Cancer ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Skin Tumor ◽  
Merkel Cell ◽  
Cytological Method ◽  
Cytological Diagnostics

Merkel cell carcinoma is a rare malignant primary skin tumor with epithelial and neuroendocrine differentiation. In the presented diagnostic case, the possibility of a cytological method in this material is a scarification biopsy.

Merkel Cell Carcinoma of the Head and Neck Compared to Other Anatomical Sites in a Real-World Setting: Importance of Surgical Therapy for Facial Tumors

2019 ◽  
Vol 36 (03) ◽  
pp. 249-254
Author(s):  
Markus V. Heppt ◽  
Michael C. Kirchberger ◽  
Gerold Schuler ◽  
Carola Berking ◽  
Lucie Heinzerling
Keyword(s):  
Clinical Outcome ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Merkel Cell Carcinoma ◽  
Proportional Hazards ◽  
Disease Free Survival ◽  
Skin Tumor ◽  
Resection Margins ◽  
Merkel Cell ◽  
Oncological Treatment

AbstractMerkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin tumor with a high propensity for nodal involvement, local recurrence, and distant metastases. Up to 50% of MCC arises on head and neck (HN), which may impede oncological treatment due to insufficiently wide excisions and a lower rate of sentinel lymph node detection due to more complicated lymph drainage. Several studies have compared the clinical outcome of HN-MCC with those of non-head and neck (NHN) MCC yielding inconsistent results. This single-center, retrospective analysis compared the clinical outcome of 26 HN-MCC patients with 30 NHN-MCC patients. Overall survival (OS) and disease-free survival (DFS) were calculated with the Kaplan–Meier method assuming proportional hazards. The mean resection margins were 1.6 and 2.0 cm for the HN and NHN cohort, respectively. Local relapses were more frequently observed in patients with HN-MCC (19 vs. 10%). Patients with HN-MCC had a median OS of 4.3 years compared with 7.5 years in patients with NHN-MCC (p = 0.277). The median OS by tumor stage was 11, 3, 2, and 3 years in stage I, II, III, and IV disease, respectively (p = 0.009). The median DFS in HN-MCC was 10 years and not reached in the cohort with NHN-MCC patients (p = 0.939). Our data suggest a trend toward poorer outcomes of HN-MCC compared with NHN-MCC. Patients with MCC on the head and neck carry a higher risk for local relapse, requiring resolute surgical treatment also in facial localizations at early stages.

scholarly journals An Aggressive Presentation of Merkel Cell Carcinoma: A Case Report

2020 ◽  
Vol 8 ◽  
pp. 232470962096371
Author(s):  
Zemni Ines ◽  
Haddad Sabrine ◽  
Fatma Saadallah ◽  
Ayadi Mohamed Ali ◽  
Charfi Lamia ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Combined Treatment ◽  
Locally Advanced ◽  
Nodal Metastasis ◽  
Skin Tumor ◽  
Merkel Cell ◽  
Old Patients ◽  
Left Groin ◽  
Therapeutic Algorithm

Merkel cell carcinoma (MCC) is a rare malignant neuroendocrine tumor more common in immunosuppressed old patients. It is characterized by a high frequency of local recurrence, regional nodal metastasis, distant metastasis, and low survival rate. The diagnosis of MCC is challenging due to its rarity and can be clinically mistaken for other skin cancer. We report a case of locally advanced MCC of the left groin with aggressive behavior that was finally controlled with a combined treatment and we collected data from the literature to discuss the appropriate therapeutic algorithm for the management of this uncommon skin tumor.

Sign in / Sign up

Export Citation Format

Share Document